Kidswell Bio Corporation AI Stock Analysis
Want to see JP:4584 full AI Analyst Report?
Kidswell Bio Corporation (4584) AI Stock Analysis
Kidswell Bio Corporation
(TSE/TYO:4584)
Kidswell Bio scores low primarily because of weak fundamentals. Despite rapid revenue growth, gross margins have deteriorated sharply, losses persist, leverage is rising, and FY2026 projections point to a return to heavy cash burn after a single positive year — a combination that raises financing and dilution risk. Valuation offers no cushion, with negative earnings and no dividend. The only meaningful offset is short-term technical momentum, as the stock has rebounded above its 20- and 50-day moving averages, though it remains far below its 100- and 200-day averages and momentum indicators are now stretched. Given the absence of earnings call or corporate event data, the score is driven almost entirely by financial performance.
Kidswell Bio Corporation (4584) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 7.35B
- Dividend Yield
- ―
- Average Volume (3M)
- 338.07K
- Price to Earnings (P/E)
- 66.1
- Beta (1Y)
- 1.17
- Revenue Growth
- -12.40%
- EPS Growth
- -64.38%
- Country
- Japan
- Employees
- 32
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Kidswell Bio Corporation Business Overview & Revenue Model
Company Description
Kidswell Bio Corporation, headquartered in Tokyo, Japan, specializes in the development of pharmaceutical treatments for rare and complex diseases. The company, which was founded in 2001 and operated as Gene Techno Science Co.,Ltd. until rebranding i...
How the Company Makes Money
Kidswell Bio’s monetization is primarily tied to the biopharmaceutical development model. Revenue may be generated through (1) licensing and out-licensing arrangements (e.g., upfront payments, milestone payments tied to development/approval events, a...
Kidswell Bio Corporation Financial Statement Overview
Summary
Financials are weak across all three statements. Revenue has scaled impressively from ¥997M (FY2021) to ¥5.1B (FY2025) with ¥6.6B projected for FY2026, but gross margins have collapsed from 88% to a projected 26.5%, indicating the growth is coming from low-value business lines. The company remains persistently unprofitable, and the near-breakeven FY2025 result reverses into a projected ¥414M net loss and negative EBIT in FY2026. The balance sheet is increasingly leveraged, with total debt rising from ¥700M to a projected ¥2.55B and debt-to-equity climbing to 1.54x, alongside a negative ROE. Cash flow is the weakest link: free cash flow has been negative in five of six periods, and the one positive operating cash flow year (FY2025, ¥937M) is projected to reverse to -¥1.09B in FY2026, raising the prospect of additional financing and shareholder dilution.
Income Statement
28NegativeBalance Sheet
25NegativeCash Flow
22Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.14B | 6.59B | 5.08B | 2.43B | 2.78B | 1.57B |
| Gross Profit | 1.58B | 1.75B | 1.64B | 1.04B | 1.53B | 1.02B |
| EBITDA | -217.23M | -138.26M | 116.26M | -1.38B | -620.45M | -531.89M |
| Net Income | -373.22M | -413.99M | -21.14M | -1.42B | -657.43M | -550.86M |
Balance Sheet | ||||||
| Total Assets | 6.13B | 6.09B | 7.01B | 5.09B | 3.89B | 3.47B |
| Cash, Cash Equivalents and Short-Term Investments | 3.23B | 3.29B | 3.00B | 2.23B | 1.07B | 1.16B |
| Total Debt | 2.48B | 2.55B | 1.84B | 2.58B | 1.95B | 700.00M |
| Total Liabilities | 4.29B | 4.43B | 5.60B | 4.25B | 2.66B | 1.77B |
| Stockholders Equity | 1.84B | 1.65B | 1.41B | 831.47M | 1.23B | 1.70B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.11B | 930.26M | -453.63M | -1.42B | -1.17B |
| Operating Cash Flow | 0 | -1.09B | 936.71M | -453.63M | -1.42B | -1.17B |
| Investing Cash Flow | 0 | -12.62M | 65.08M | 0 | -28.82M | 526.51M |
| Financing Cash Flow | 0 | 1.40B | -240.06M | 1.62B | 1.36B | 369.08M |
Kidswell Bio Corporation Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4584, the sentiment is Neutral. The current price of 148.00 is below the 20-day moving average (MA) of 148.80, below the 50-day MA of 158.30, and below the 200-day MA of 192.26, indicating a bearish trend. The MACD of -4.21 indicates Positive momentum. The RSI at 47.21 is Neutral, neither overbought nor oversold. The STOCH value of 47.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4584.
Kidswell Bio Corporation Peers Comparison
Overall Rating
JP:497844Neutral
JP:777442Neutral
JP:459339Underperform- JP:458438Underperform
JP:459938Underperform
JP:777637Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4978 | 44Neutral | JPY 11.65B | -25.06 | ― | ― | -8.23% | -48.10% |
| JP:7774 | 42Neutral | JPY 26.52B | -73.78 | ― | ― | 17.05% | 10.47% |
| JP:4593 | 39Underperform | JPY 30.90B | -13.76 | ― | ― | -51.55% | 52.19% |
| JP:4584 | 38Underperform | JPY 7.49B | 66.07 | ― | ― | -12.40% | -64.38% |
| JP:4599 | 38Underperform | JPY 7.33B | -3.94 | ― | ― | ― | 4.85% |
| JP:7776 | 37Underperform | JPY 6.70B | -5.83 | ― | ― | -49.43% | -3.77% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4584 | Kidswell Bio Corporation | 148.00 | -96.00 | -39.34% | |
| JP:4593 | Healios KK | 228.00 | -223.00 | -49.45% | |
| JP:4599 | StemRIM Inc. | 117.00 | -161.00 | -57.91% | |
| JP:4978 | ReproCELL Inc. | 109.00 | -48.00 | -30.57% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 653.00 | 175.00 | 36.61% | |
| JP:7776 | CellSeed Inc. | 169.00 | -232.00 | -57.86% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 21, 2026